Log In
BCIQ
Print this Print this
 

Avdesp, biosimilar darbepoetin alfa

  Manage Alerts
Collapse Summary General Information
Company Avesthagen Ltd.
DescriptionBiosimilar of darbepoetin alfa, a recombinant erythropoietin (EPO)
Molecular Target
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAnemia
Indication DetailsTreat anemia due to chronic kidney disease (CKD); Treat chemotherapy-induced anemia (CIA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/25/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today